This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row

Johnson & Johnson (NYSE: JNJ) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%. That extended its dividend growth streak to an impressive 63 years in a row, keeping it in the elite group of Dividend Kings, companies with 50 or more years of annual dividend increases.

That payout boost pushes the company's forward dividend yield up to 3.4%, more than double the S&P 500's dividend yield of 1.4%. Johnson & Johnson's high-yielding payout is as healthy as they come, making it a super safe option for those desiring to collect passive dividend income.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

In peak financial health

Johnson & Johnson has one of the healthiest financial profiles in the world. The healthcare giant has a pristine AAA bond rating. It's one of only two companies in the world with a top credit rating, which is higher than the U.S. government.

The company ended the first quarter of this year with only $13.5 billion of net debt: $38.8 billion of cash against $52.3 billion of debt. While that might sound like a lot, it's a paltry total for a company with a $370 billion market cap. It's also a very manageable amount, considering that Johnson & Johnson produced $3.4 billion in free cash flow during its most recent quarter. That was more than enough cash to cover the company's $3 billion dividend outlay in the period.

Last year, the company produced $20 billion in free cash flow. That was a more than $1.6 billion improvement from 2023 despite higher litigation settlement payments, higher taxes, and eight months of cash flow from its former consumer health business, Kenvue, in 2023. That growing free cash flow easily covered the company's full-year dividend cost of $11.8 billion.

Healthy investments to continue growing

The healthcare company produces significant free cash flow despite investing heavily in research and development (R&D) to discover and test new innovative medicines and medical technologies. Last year, the company poured $17 billion into R&D, accounting for 19.4% of its sales, which kept it as one of the top R&D investors across all industries. Johnson & Johnson has continued to spend heavily on R&D this year, investing $3.2 billion in the first quarter.

It has also deployed significant cash into strategic inorganic growth opportunities. It spent over $14 billion in the first quarter to close its acquisition of Intra-Cellular Therapies. That followed deals last year for Shockwave Medical, $13.1 billion; Ambrx, $1.9 billion; and V-Wave, $600 million. These acquisitions helped fill holes in its pipelines, accelerate innovation, and add new products to its MedTech platform. The company's ability to maintain such a strong balance sheet amid this massive shopping spree showcases its financial might.

Johnson & Johnson's hefty investments position it to continue growing its revenue and earnings. The company's long-term target is to grow its operational sales at a 5% to 7% compound annual rate from 2025 through 2030. That sales growth should drive its earnings and free cash flow higher, enabling the company to continue increasing its dividend.

As bankable a dividend as you'll find

All investments carry varying levels of risk. Johnson & Johnson's high-yielding dividend is at the low end of the spectrum. The healthcare giant produces prodigious free cash flow that easily covers its payout. It also has one of the strongest balance sheets in the world. Those features allow the company to make heavy investments in R&D and acquisitions to drive future growth. That growth should enable Johnson & Johnson to continue reigning supreme as one of the top dividend stocks to own for a safe and secure income stream that rises each year.

Should you invest $1,000 in Johnson & Johnson right now?

Before you buy stock in Johnson & Johnson, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $526,499!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $687,684!*

Now, it’s worth noting Stock Advisor’s total average return is 818% — a market-crushing outperformance compared to 156% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 14, 2025

Matt DiLallo has positions in Johnson & Johnson and Kenvue. The Motley Fool has positions in and recommends Kenvue. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.